EP Patent

EP3383392A1 — Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Assigned to Global Blood Therapeutics Inc · Expires 2018-10-10 · 8y expired

What this patent protects

Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.

USPTO Abstract

Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(l-isopropyl-lH-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.

Drugs covered by this patent

Patent Metadata

Patent number
EP3383392A1
Jurisdiction
EP
Classification
—
Expires
2018-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Global Blood Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.